Health TrialsbyHealthPanel

Serum CTGF in Chronic Plantar Fasciitis

ConditionPlantar Fasciitis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorKanuni Sultan Suleyman Training and Research Hospital

About this trial

This observational study aims to evaluate serum Connective Tissue Growth Factor (CTGF/CCN2) levels in patients with chronic plantar fasciitis compared with asymptomatic controls. The study will also assess the associations between serum CTGF levels and clinical and ultrasonographic characteristics of chronic plantar fasciitis.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18-65 years.

Written informed consent.

For the patient group: chronic plantar heel pain for at least 3 months, pain during the first steps in the morning or after prolonged rest, tenderness over the medial calcaneal tubercle, and clinical and ultrasonographic findings consistent with chronic plantar fasciitis.

For the control group: asymptomatic individuals without a previous diagnosis or clinical and ultrasonographic findings of plantar fasciitis.

Disqualifiers

Tarsal tunnel syndrome, calcaneal stress fracture, plantar fascia rupture, Achilles tendinopathy, heel fat pad syndrome, plantar fibromatosis, or other foot conditions causing plantar heel pain.

Diabetes mellitus.

Inflammatory rheumatic diseases or gout.

Chronic kidney or liver disease.

Trial population

Adults aged 18-65 years, including patients with chronic plantar fasciitis and asymptomatic controls without clinical or ultrasonographic findings of plantar fasciitis.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

60 Participants
are grouped into 2 trial groups
Group A: Chronic Plantar Fasciitis Group
Group B: Control Group

Trial outcomes

Primary outcomes

1

Serum CTGF/CCN2 Level

Serum Connective Tissue Growth Factor (CTGF/CCN2) levels will be measured in patients with chronic plantar fasciitis and asymptomatic controls.

Time frame
At baseline

Secondary outcomes

1

Pain Severity

Pain severity will be assessed using a Visual Analog Scale (VAS), and its association with serum CTGF/CCN2 levels will be evaluated.

Time frame
At baseline
2

Foot Function Index

Functional status will be assessed using the Foot Function Index (FFI), and its association with serum CTGF/CCN2 levels will be evaluated.

Time frame
At baseline
3

Plantar Fascia Thickness

Plantar fascia thickness will be measured by musculoskeletal ultrasonography, and its association with serum CTGF/CCN2 levels will be evaluated.

Time frame
At baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Kanuni Sultan Suleyman Training and Research Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: